cangen biotechnologies inc.

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

Cangen Biotechnologies Inc. And Dai Nippon Printing Co., Ltd. Move Forward With Development Of An Early Stage Lung Cancer Diagnostic

Collaboration has resulted in successful first "proof of principal" phase BALTIMORE -- Cangen Biotechnologies, Inc. and Dai Nippon Printing Co., Ltd. DNP of Japan are pleased to announce that they will move forward with a clinical trial phase of an early stage lung cancer diagnostic. Based on successful...

Tags: Cangen Biotechnologies Inc., Dai Nippon Printing Co. Ltd., DNP

Research articles 2008-08-12

Additional Resources

Cangen Biotechnologies and Olympus to Collaborate on Development of High-Throughput Molecular Diagnostic Test for Lung Cancer

BETHESDA, Md. -- Cangen Biotechnologies, Inc. today announced a research collaboration with Olympus Corporation for the development of a hybrid DNA-based and protein-based diagnostic test for use in the detection of lung cancer. This collaboration will provide Cangen Biotechnologies with access to Olympus' microarray technology to enable the DNA-based portion...

Tags: DNA, Molecular Inc., Olympus Corp.

Research articles 2005-05-25

Cangen Biotechnologies and Olympus Expand Collaboration to Develop High-Throughput Molecular Diagnostic Test for Early Detection of Lung Cancer

BETHESDA, Md. -- Cangen Biotechnologies, Inc. today announced the expansion of its ongoing research collaboration with Olympus Corporation, initiated in May 2005, to develop a hybrid DNA-based and protein-based diagnostic test for use in the early detection of lung cancer. The expanded collaboration includes funding for a prospective clinical study.

Tags: collaboration, Molecular Inc., Olympus Corp.

Research articles 2006-01-06

Commonwealth Biotechnologies, Inc. to Participate in NCI Sponsor Clinical Trial; Conduct of Molecular Screening Assays for Early Detection of Bladder Cancer Genetic Markers

RICHMOND, Va. -- Commonwealth Biotechnologies, Inc. (NASDAQ: CBTE), is pleased to announce that it has been qualified and selected by the National Cancer Institute to perform molecular assays as part of a clinical trial to test the efficacy of the first DNA-based bladder cancer diagnostic. CBI will perform the assay...

Tags: clinical trial, Molecular Inc., Network Computer Inc.

Research articles 2004-09-30